Zymeworks Inc (ZYME)

Form 8-K - Current report

Zymeworks to Acquire Theravance Biopharma, Inc.

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic...

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery PR Newswire VANCOUVER, BC, June...

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of...

Form 8-K - Current report

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology...

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA...

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers...

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class...

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a...

Form 4 - Statement of changes in beneficial ownership of securities